INSUFICIENCIA CARDIACA

Insuf Card 2016;11 (3): 115-121

Pulmonary arterial hypertension in adult congenital heart disease

Impact and outcome

Data from the GUTI-GUCH Registry

Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliva, María del Carmen Rubio, Mariana López Daneri, Isabel Torres, Inés Abella, Álvaro Sosa Liprandi, Liliana Noemí Nicolosi, María Grippo

Introduction

Due to early diagnosis and advances in surgical and endovascular treatment, adult congenital heart disease (ACHD) is one of the fastest growing cardiology subgroups in recent years.  It is calculated that 85-90% of patients with congenital heart disease reach adulthood. The survival of these patients generates complications and sequelae that contribute to higher rates of hospitalization and new surgeries, among other procedures.

During its progression, an estimated 5 to 10% of patients with ACHD will develop pulmonary hypertension (PH), making it currently the most frequent cause of pulmonary arterial hypertension (PAH) after connective tissue disease. The occurrence of PAH is related to a worse prognosis for the patient.

The objective of this study was to analyze the epidemiological characteristics and clinical and pharmacological treatment of patients with PAH and their impact on survival.

OR:

The objective of this study was to analyze the epidemiological and clinical characteristics and pharmacological treatment of patients with PAH and their impact on survival.

OR

The objective of this study was to analyze the epidemiological, clinical and pharmacotherapy characteristics of patients with PAH and their impact on survival.